Literature DB >> 23099993

Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center.

T Zeller1, K Muenstedt, C Stoll, J Schweder, B Senf, E Ruckhaeberle, S Becker, H Serve, J Huebner.   

Abstract

PURPOSE: About 40-50 % of cancer patients use complementary and alternative medicine (CAM). Women, and especially those with gynecological cancers, are more active in this field than men. The goal of our study was to estimate the likelihood of CAM use and the likelihood of interactions of CAM with cancer therapy in the setting of a gynecological outpatient clinic at a German Comprehensive Cancer Center (CCC).
METHODS: One hundred consecutive gynecological outdoor patients of the CCC in Frankfurt am Main in Germany were interviewed with a standardized questionnaire on CAM use. An investigation on potential interactions was done by matching a scientific database systematically.
RESULTS: Sixty-nine of the interviewed 100 women received chemotherapy, 23 endocrine therapy and 41 monoclonal antibodies. In total, 64 % used CAM, 48 % used at least one substance-bound CAM. In 17 out of those 48 cases (35 %), interactions were unlikely, whereas they were probable in 14 patients (29 %). Thus, a third of all patients in this study were in danger of interactions. More than half of all CAM users and three quarters of users of substance-bound CAM are at risk of interactions. This number is independent of whether the patient is taking chemotherapy, endocrine therapy or antibodies.
CONCLUSIONS: The frequency of CAM use we found is in line with international data from CCCs in the USA. To our knowledge, this is the first study publishing data on the frequency of potential interactions. Thus, an initiative to protect women from the dangers of uncontrolled CAM use is urgently needed. In the discussion, we propose a concept of how to achieve this aim.

Entities:  

Mesh:

Year:  2012        PMID: 23099993     DOI: 10.1007/s00432-012-1336-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  14 in total

1.  Use of complementary medicine by adult patients participating in cancer clinical trials.

Authors:  A Sparber; L Bauer; G Curt; D Eisenberg; T Levin; S Parks; S M Steinberg; J Wootton
Journal:  Oncol Nurs Forum       Date:  2000-05       Impact factor: 2.172

Review 2.  Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review.

Authors:  Christine M Velicer; Cornelia M Ulrich
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

Review 3.  How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis.

Authors:  Markus Horneber; Gerd Bueschel; Gabriele Dennert; Danuta Less; Erik Ritter; Marcel Zwahlen
Journal:  Integr Cancer Ther       Date:  2011-10-21       Impact factor: 3.279

4.  Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology.

Authors:  M A Richardson; T Sanders; J L Palmer; A Greisinger; S E Singletary
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

Review 5.  Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies.

Authors:  A Robinson; M R McGrail
Journal:  Complement Ther Med       Date:  2004 Jun-Sep       Impact factor: 2.446

6.  Complementary and alternative medicine use by patients enrolled onto phase I clinical trials.

Authors:  Grace K Dy; Lishan Bekele; Lorelei J Hanson; Alfred Furth; Sumithra Mandrekar; Jeff A Sloan; Alex A Adjei
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

7.  Disclosure to physicians of CAM use by breast cancer patients: findings from the Women's Healthy Eating and Living Study.

Authors:  Gordon A Saxe; Lisa Madlensky; Sheila Kealey; David P H Wu; Karen L Freeman; John P Pierce
Journal:  Integr Cancer Ther       Date:  2008-09       Impact factor: 3.279

8.  Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer.

Authors:  Jessica W Henderson; Rebecca J Donatelle
Journal:  Altern Ther Health Med       Date:  2004 Jan-Feb       Impact factor: 1.305

9.  The relationship between cancer locus of control and complementary and alternative medicine use by women diagnosed with breast cancer.

Authors:  Jessica W Henderson; Rebecca J Donatelle
Journal:  Psychooncology       Date:  2003 Jan-Feb       Impact factor: 3.894

Review 10.  Lesson from comparison of CAM use by women with female-specific cancers to others: it's time to focus on interaction risks with CAM therapies.

Authors:  Valerie S Eschiti
Journal:  Integr Cancer Ther       Date:  2007-12       Impact factor: 3.279

View more
  35 in total

1.  Perception of cancer patients of their disease, self-efficacy and locus of control and usage of complementary and alternative medicine.

Authors:  Marie-Desirée Ebel; Ivonne Rudolph; Christian Keinki; Andrea Hoppe; Ralph Muecke; Oliver Micke; Karsten Muenstedt; Jutta Huebner
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-22       Impact factor: 4.553

2.  Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma.

Authors:  Carmen Loquai; Dagmar Dechent; Marlene Garzarolli; Martin Kaatz; Katharina C Kaehler; Peter Kurschat; Frank Meiss; Annette Stein; Dorothee Nashan; Oliver Micke; Ralph Muecke; Karsten Muenstedt; Christoph Stoll; Irene Schmidtmann; Jutta Huebner
Journal:  Med Oncol       Date:  2016-04-18       Impact factor: 3.064

3.  Nutritional care of cancer patients: a survey on patients' needs and medical care in reality.

Authors:  J Maschke; U Kruk; K Kastrati; J Kleeberg; D Buchholz; N Erickson; J Huebner
Journal:  Int J Clin Oncol       Date:  2016-08-02       Impact factor: 3.402

4.  Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma.

Authors:  Chengkuan Cai; Jingyuan Tang; Baixin Shen; Liucheng Ding; Yunpeng Shao; Zhengsen Chen; Yinchao Ma; Haoliang Xue; Zhongqing Wei
Journal:  Exp Ther Med       Date:  2017-07-31       Impact factor: 2.447

5.  Complementary and alternative medicine in radiation oncology : Survey of patients' attitudes.

Authors:  Sabrina Lettner; Kerstin A Kessel; Stephanie E Combs
Journal:  Strahlenther Onkol       Date:  2017-01-27       Impact factor: 3.621

6.  Complementary and Alternative Medicine in Palliative Care: A Comparison of Data From Surveys Among Patients and Professionals.

Authors:  Ralph Muecke; Magdalena Paul; Christina Conrad; Christoph Stoll; Karsten Muenstedt; Oliver Micke; Franz J Prott; Jens Buentzel; Jutta Huebner
Journal:  Integr Cancer Ther       Date:  2015-07-26       Impact factor: 3.279

7.  Patients with advanced cancer and their usage of complementary and alternative medicine.

Authors:  Magda Paul; B Davey; B Senf; C Stoll; K Münstedt; R Mücke; Oliver Micke; F J Prott; J Buentzel; Jutta Hübner
Journal:  J Cancer Res Clin Oncol       Date:  2013-07-06       Impact factor: 4.553

8.  Use of complementary and alternative medicine by patients with cancer: a cross-sectional study at different points of cancer care.

Authors:  J Kleine Wortmann; A Bremer; H T Eich; H P Kleine Wortmann; A Schuster; J Fühner; J Büntzel; R Muecke; F J Prott; J Huebner
Journal:  Med Oncol       Date:  2016-06-14       Impact factor: 3.064

9.  The use of complementary and alternative medicine by patients in routine care and the risk of interactions.

Authors:  Rachel Firkins; Hannah Eisfeld; Christina Keinki; Jens Buentzel; Andreas Hochhaus; Thorsten Schmidt; Jutta Huebner
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-22       Impact factor: 4.553

10.  An assessment of the impact of herb-drug combinations used by cancer patients.

Authors:  Saud M Alsanad; Rachel L Howard; Elizabeth M Williamson
Journal:  BMC Complement Altern Med       Date:  2016-10-18       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.